Citations

Showing 10 of 108135 citations.

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data
Silberstein, Stephen D., DeGryse, Ronald E., Adams, Aubrey Manack, Dodick, David W. , Lipton, Richard B. , Diener, Hans‐Christoph

Mayo Clinic

Cephalalgia | May 21, 2019 | Volume: 39 | Issue: 8 | Pages: 945-956

10.1177/0333102418825382 | PMID 31112399 Get It

Background The Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis assessed time of onset of onabotulinumtoxinA after the first treatment in total and responder populations and consistency weekly through five treatment cycles. Methods In the 24-week, double-blind, placebo-controlled phase of PREEMPT, individuals were randomized 1:1 to onabotulinumtoxinA (155-195 U) or placebo every 12 weeks for two cycles. The primary pooled efficacy variable was change in headache days per 28 days at week 24. We assessed change in headache and migraine/probable migraine (hereafter migraine) days/week compared with baseline week 4. Results Baseline mean (SD) headache days/week (week 4 of baseline) for onabotulinumtoxinA (n = 688) and placebo (n = 696) were similar (4.8 [1.6] vs. 4.8 [1.6] days/week, respectively), as were migraine days/week (4.6 [1.7] vs. 4.6 [1.7] days/week). The effect of onabotulinumtoxinA on change in headache and migraine days/week was significantly greater than placebo at week 1, persisting from week 3 after the first treatment (−1.6 [2.2] vs. −1.1 [2.2] headache days/week [ p < 0.001] and −1.6 [2.2] vs. −1.1 [2.2] migraine days/week [ p < 0.001]). Headache and migraine days decreased in onabotulinumtoxinA responders beginning 1 week after treatment 1. Conclusions Treatment with onabotulinumtoxinA is associated with significant reductions in headache and migraine days/week at week 1, persisting after week 3, compared with placebo. Combined with earlier reports showing onabotulinumtoxinA treatment results in a persistent and progressive reduction in headache days over 56 weeks, it is suggested peak benefit may require multiple treatments. Trial registration number ClinicalTrials.gov: NCT00156910 and NCT00168428.
18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study
Zattoni, Fabio , Incerti, Elena , Moro, Fabrizio , Moschini, Marco , Picchio, Maria , Fallanca, Federico , Briganti, Alberto , Gallina, Andrea , Schiavina, Riccardo , Brunocilla, Eugenio, Rambaldi, Ilaria, Lowe, Val J. , Karnes, R. Jeffrey, Evangelista, Laura , Gallina, Andrea , Karnes, Jeffrey R, Evangelista, Laura , Moschini, Marco , Zattoni, Fabio , Castellucci, Paolo , Panareo, Stefano , Fanti, Stefano

Mayo Clinic

Cancers | May 21, 2019 | Volume: 11 | Issue: 5 | Pages: 700

10.3390/cancers11050700 | PMID 31137599 Get It

Objectives: To evaluate the ability of 18F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict survivorship of patients with bladder cancer (BC) and/or upper urinary tract carcinoma (UUTC). Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study. Disease management after the introduction of FDG PET/CT in the diagnostic algorithm was assessed in all patients. Kaplan-Meier and log-rank analysis were computed for survival assessment. A Cox regression analysis was used to identify predictors of recurrence and death, for BC, UUTC, and concomitant BC and UUTC. Results: Data from 286 patients were collected. Of these, 212 had a history of BC, 38 of UUTC and 36 of concomitant BC and UUTC. Patient management was changed in 114/286 (40%) UC patients with the inclusion of FDG PET/CT, particularly in those with BC, reaching 74% (n = 90/122). After a mean follow-up period of 21 months (Interquartile range: 4–28 mo.), 136 patients (47.4%) had recurrence/progression of disease. Moreover, 131 subjects (45.6%) died. At Kaplan-Meier analyses, patients with BC and positive PET/CT had a worse overall survival than those with a negative scan (log-rank < 0.001). Furthermore, a negative PET/CT scan was associated with a lower recurrence rate than a positive examination, independently from the primary tumor site. At multivariate analysis, in patients with BC and UUTC, a positive FDG PET/CT resulted an independent predictor of disease-free and overall survival (p < 0,01). Conclusions: FDG PET/CT has the potential to change patient management, particularly for patients with BC. Furthermore, it can be considered a valid survival prediction tool after primary treatment in patients with recurrent UC. However, a firm recommendation cannot be made yet. Further prospective studies are necessary to confirm our findings.
Finding Your First Job After Fellowship
LeMond, Lisa , Fender, Erin A. , Lemond, Lisa M, Kalra, Ankur

Mayo Clinic

European Heart Journal | May 21, 2019 | Volume: 40 | Issue: 20 | Pages: 1581-1583

10.1093/eurheartj/ehz277 | PMID 31111885 Get It

Predictors of long‐term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction
Zhu, Changsheng , Tang, Bing , Cui, Hao , Wang, Shengwei , Xiao, Minghu , Chen, Zixian , Meng, Yanhai , Zhao, Shihua , Song, Yunhu, Yu, Qinjun , Wang, Shuiyun , Wang, Shuiyun

Mayo Clinic

Journal of Cardiac Surgery | May 21, 2019 | Volume: 34 | Issue: 7 | Pages: 533-540

10.1111/jocs.14072 | PMID 31111576 Get It

Late‐life time‐restricted feeding and exercise differentially alter healthspan in obesity
Schafer, Marissa , Mazula, Daniel L., Brown, Ashley K. , White, Thomas A. , Atkinson, Elizabeth J. , Pearsall, Vesselina, Aversa, Zaira, Verzosa, Grace, Matveyenko, Aleksey V. , Miller, Jordan D. , Schafer, Marissa J, Pearsall, Vesselina M, Verzosa, Grace C, Smith, Leslie A, Matveyenko, Aleksey, Schafer, Marissa J , Smith, Leslie , LeBrasseur, Nathan K. , Miller, Jordan

Mayo Clinic

Aging Cell | May 21, 2019 | Volume: 18 | Issue: 4 | Pages: No page available

10.1111/acel.12966 | PMID 31111669 Get It

AbstractAging and obesity increase multimorbidity and disability risk, and determining interventions for reversing healthspan decline is a critical public health priority. Exercise and time‐restricted feeding (TRF) benefit multiple health parameters when initiated in early life, but their efficacy and safety when initiated at older ages are uncertain. Here, we tested the effects of exercise versus TRF in diet‐induced obese, aged mice from 20 to 24 months of age. We characterized healthspan across key domains: body composition, physical, metabolic, and cardiovascular function, activity of daily living (ADL) behavior, and pathology. We demonstrate that both exercise and TRF improved aspects of body composition. Exercise uniquely benefited physical function, and TRF uniquely benefited metabolism, ADL behavior, and circulating indicators of liver pathology. No adverse outcomes were observed in exercised mice, but in contrast, lean mass and cardiovascular maladaptations were observed following TRF. Through a composite index of benefits and risks, we conclude the net healthspan benefits afforded by exercise are more favorable than those of TRF. Extrapolating to obese older adults, exercise is a safe and effective option for healthspan improvement, but additional comprehensive studies are warranted before recommending TRF.
Preclinical Feasibility of the Bio-Airbrush for Arthroscopic Cell-Based Cartilage Repair
Dijkstra, Koen, Huitsing, Roeland P.J., Kouwenhoven, Jan Willem M., Bleys, Ronald L. A. W. , Vonk, Luciënne A. , Saris, Daniël B.F. , Vonk, Lucienne A , Custers, Roel J.H. , Kouwenhoven, Jan-Willem M.

Mayo Clinic

Tissue Engineering Part C: Methods | May 21, 2019 | Volume: 25 | Issue: 7 | Pages: 379-388

10.1089/ten.tec.2019.0050 | PMID 31111789 Get It

Objective: To investigate the preclinical feasibility of using bio-airbrush technology for the fully arthroscopic treatment of cartilage defects with a combination of cells and biomaterials. Design: A combination of in vitro , ex vivo , and cadaveric in situ experiments was performed, to evaluate the preclinical feasibility of using bio-airbrush technology for cartilage repair. Cartilage matrix production after airbrushing cells was evaluated. Subsequently, the influence of different spray parameters on successful defect fill was studied. Finally, the surgical feasibility of using bio-airbrush technology was evaluated in situ in cadaveric knees. Results: The most important findings of the presented study are that the matrix producing capacity of the cells was not hampered by airbrushing, air pressure and defect location were important parameters to consider, and using the bio-airbrush was found to be surgically feasible in a CO 2 -insufflated arthroscopic procedure in cadaveric knees. Conclusions: Bio-airbrush using CO 2 arthroscopy would facilitate fully arthroscopic application of (cell laden) two-component in situ gelating biomaterials to cartilage defects, as a treatment for cartilage repair. This would shift the conventional procedures, which are commonly performed using a (mini-)arthrotomy, toward arthroscopy. Impact Statement This study shows that a bio-airbrush can be a clinically feasible instrument for the use in cell transplantations to repair knee cartilage defects. This technology would enable a shift from cartilage repair procedures, which are mostly performed using an arthrotomy, toward a fully arthoscopic approach. In addition, the technology presented could possibly be translated to other fields of research where controlled in situ deposition of cells is required, such as treatment of burn wounds/ulcers/others. Our research has shown that the use of an airbrush is safe, without harming cell viability and performance.
A Preference-Based Model of Care: An Integrative Theoretical Model of the Role of Preferences in Person-Centered Care
Haitsma, Kimberly Van, Abbott, Katherine , Arbogast, Annabelle, Bangerter, Lauren R. , Heid, Allison R. , Behrens, Liza , Madrigal, Caroline , Abbott, Katherine M

Mayo Clinic

The Gerontologist | May 21, 2019 | Volume: 60 | Issue: 3 | Pages: 376-384

10.1093/geront/gnz075 | PMID 31152589 Get It

Abstract Knowledge of individuals’ everyday preferences is a cornerstone of person-centered care (PCC). Initial evidence demonstrates the positive impact of honoring preferences in care for older adults receiving long-term services and supports (LTSS). Yet, the mechanisms through which preference-based care affects individual well-being remain poorly understood. This article proposes a theoretical model of PCC entitled the Preference-Based Model of Care that integrates the Theory of Human Motivation, Self-determination Theory, the Competence-Press Model of person and environment fit, the Living Systems Framework, and the Broaden-and-Build theory of positive emotions to deepen our understanding of the processes through which preference-based care affects well-being among older adults receiving LTSS. The Preference-Based Model of Care illustrates how goal-directed behaviors facilitate need fulfillment through the expression of individual preferences and how these behaviors mediate the relationship between person–environment fit and affect balance within a particular social, cultural, and political context. The Preference-Based Model of Care can advance research on PCC in LTSS and can inform LTSS clinical practice guidelines for older adults, regardless of functional or cognitive capacity.
Distortion‐free imaging: A double encoding method (DIADEM) combined with multiband imaging for rapid distortion‐free high‐resolution diffusion imaging on a compact 3T with high‐performance gradients
In, Myung‐Ho , Tan, Ek T. , Trzasko, Joshua D. , Shu, Yunhong , Yarach, Uten , Tao, Shengzhen , Gray, Erin M. , Tao, Shengzhen , Tan, Ek T , Kang, Daehun , Huston, John , Bernstein, Matt A. , In, Myung-Ho

Mayo Clinic

Journal of Magnetic Resonance Imaging | May 21, 2019 | Volume: 51 | Issue: 1 | Pages: 296-310

10.1002/jmri.26792 | PMID 31111581 Get It

BackgroundDistortion‐free, high‐resolution diffusion imaging using DIADEM (Distortion‐free Imaging: A Double Encoding Method), proposed recently, has great potential for clinical applications. However, it can suffer from prolonged scan times and its reliability for quantitative diffusion imaging has not been evaluated.PurposeTo investigate the clinical feasibility of DIADEM‐based high‐resolution diffusion imaging on a novel compact 3T (C3T) by evaluating the reliability of quantitative diffusion measurements and utilizing both the high‐performance gradients (80 mT/m, 700 T/m/s) and the sequence optimization with the navigator acquisition window reduction and simultaneous multislice (multiband) imaging.Study TypeProspective feasibility study.Phantom/SubjectsDiffusion quality control phantom scans to evaluate the reliability of quantitative diffusion measurements; 36 normal control scans for B0‐field mapping; six healthy and two patient subject scans with a brain tumor for comparisons of diffusion and anatomical imaging.Field Strength/Sequence3T; the standard single‐shot echo‐planar‐imaging (EPI), multishot DIADEM diffusion, and anatomical (2D‐FSE [fast‐spin‐echo], 2D‐FLAIR [fluid‐attenuated‐inversion‐recovery], and 3D‐MPRAGE [magnetization prepared rapid acquisition gradient echo]) imaging.AssessmentThe scan time reduction, the reliability of quantitative diffusion measurements, and the clinical efficacy for high‐resolution diffusion imaging in healthy control and brain tumor volunteers.Statistical TestBland–Altman analysis.ResultsThe scan time for high in‐plane (0.86 mm2) resolution, distortion‐free, and whole brain diffusion imaging were reduced from 10 to 5 minutes with the sequence optimizations. All of the mean apparent diffusion coefficient (ADC) values in phantom were within the 95% confidence interval in the Bland–Altman plot. The proposed acquisition with a total off‐resonance coverage of 597.2 Hz wider than the expected bandwidth of 500 Hz in human brain could yield a distortion‐free image without foldover artifacts. Compared with EPI, therefore, this approach allowed direct image matching with the anatomical images and enabled improved delineation of the tumor boundaries.Data ConclusionThe proposed high‐resolution diffusion imaging approach is clinically feasible on C3T due to a combination of hardware and sequence improvements.Level of Evidence3Technical EfficacyStage 1 J. Magn. Reson. Imaging 2020;51:296–310.